Aumolertinib Explained
| Tradename: | Ameile |
| Atc Prefix: | L01 |
| Atc Suffix: | EB11 |
| Legal Status: | CN: Rx-only |
| Synonyms: | Almonertinib; HS-10296 |
| Cas Number: | 1899921-05-1 |
| Pubchem: | 121280087 |
| Unii: | T4RS462G19 |
| Drugbank: | DB16640 |
| Chembl: | 4761468 |
| Chemspiderid: | 75535991 |
| Iuphar Ligand: | 11136 |
| Iupac Name: | N-[5-[[4-(1-Cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide |
| C: | 30 |
| H: | 35 |
| N: | 7 |
| O: | 2 |
| Stdinchi: | 1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34) |
| Stdinchikey: | DOEOECWDNSEFDN-UHFFFAOYSA-N |
| Smiles: | CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC |
Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer.[1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).[2]
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.[3] [4]
Notes and References
- Shirley M, Keam SJ . Aumolertinib: A Review in Non-Small Cell Lung Cancer . Drugs . 82 . 5 . 577–584 . April 2022 . 35305259 . 10.1007/s40265-022-01695-2 .
- Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE) . Johnson ML, Miller VA, Patel S, Zhao Y, Cheng L, Ali SM, Wooten M, Daniel DB . Journal of Clinical Oncology . 41 . 16 . 10.1200/JCO.2023.41.16_suppl.TPS915 . 2024-04-17 .
- Web site: Almonertinib Approved in China for EGFR T79M+ NSCLC . March 19, 2020 . onclive.com .
- Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, Chang GC, Lu Y, Pan H, Chiu CH, Wang Z, Feng J, Zhou J, Xu X, Guo R, Chen J, Yang H, Chen Y, Yu Z, Shiah HS, Wang CC, Yang N, Fang J, Wang P, Wang K, Hu Y, He J, Wang Z, Shi J, Chen S, Wu Q, Sun C, Li C, Wei H, Cheng Y, Su WC, Hsia TC, Cui J, Sun Y, Ou SI, Zhu VW, Chih-Hsin Yang J . Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial . Journal of Thoracic Oncology . 17 . 3 . 411–422 . March 2022 . 34801749 . 10.1016/j.jtho.2021.10.024 . free .
